Shareholders have faith in loss-making Protagonist Therapeutics (NASDAQ:PTGX) as stock climbs 7.3% in past week, taking three-year gain to 83%

By
Simply Wall St
Published
September 27, 2021
NasdaqGM:PTGX
Source: Shutterstock

It certainly might concern Protagonist Therapeutics, Inc. (NASDAQ:PTGX) shareholders to see the share price down 61% in just 30 days. But that doesn't change the fact that the returns over the last three years have been pleasing. In fact, the company's share price bested the return of its market index in that time, posting a gain of 83%.

Since it's been a strong week for Protagonist Therapeutics shareholders, let's have a look at trend of the longer term fundamentals.

See our latest analysis for Protagonist Therapeutics

Because Protagonist Therapeutics made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. When a company doesn't make profits, we'd generally expect to see good revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

Protagonist Therapeutics actually saw its revenue drop by 11% per year over three years. Despite the lack of revenue growth, the stock has returned 22%, compound, over three years. If the company is cutting costs profitability could be on the horizon, but the revenue decline is a prima facie concern.

The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).

earnings-and-revenue-growth
NasdaqGM:PTGX Earnings and Revenue Growth September 27th 2021

Balance sheet strength is crucial. It might be well worthwhile taking a look at our free report on how its financial position has changed over time.

A Different Perspective

While the broader market gained around 37% in the last year, Protagonist Therapeutics shareholders lost 5.8%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 2% over the last half decade. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. It's always interesting to track share price performance over the longer term. But to understand Protagonist Therapeutics better, we need to consider many other factors. For example, we've discovered 4 warning signs for Protagonist Therapeutics (1 shouldn't be ignored!) that you should be aware of before investing here.

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

If you decide to trade Protagonist Therapeutics, use the lowest-cost* platform that is rated #1 Overall by Barron's, Interactive Brokers. Trade stocks, options, futures, forex, bonds and funds on 135 markets, all from a single integrated account.Promoted

Discounted cash flow calculation for every stock

Simply Wall St does a detailed discounted cash flow calculation every 6 hours for every stock on the market, so if you want to find the intrinsic value of any company just search here. It’s FREE.

Make Confident Investment Decisions

Simply Wall St's Editorial Team provides unbiased, factual reporting on global stocks using in-depth fundamental analysis.
Find out more about our editorial guidelines and team.